MSF challenges Gilead patent application in China

Médecins Sans Frontières (MSF) has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

MSF challenges Gilead patent in China

20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.

Big Pharma

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

17 September 2018 The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.

Europe

MSF urges EU to rid market of ‘avoidable suffering’ from SPCs

30 November 2020 Médecins Sans Frontières has warned that the European Commission’s commitment to the supplementary protection certificate system risks undermining its promise to improve drug accessibility.

More on this story

Asia

MSF challenges Gilead patent in China

20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.

Big Pharma

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

17 September 2018 The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.

Europe

MSF urges EU to rid market of ‘avoidable suffering’ from SPCs

More on this story

Asia

MSF challenges Gilead patent in China

20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.

Big Pharma

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

17 September 2018 The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.

Europe

MSF urges EU to rid market of ‘avoidable suffering’ from SPCs